Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Tocilizumab by Chugai Pharmaceutical for Septic Shock: Likelihood of Approval
Tocilizumab is under clinical development by Chugai Pharmaceutical and currently in Phase II for Septic Shock. According to GlobalData, Phase...
Tocilizumab by Chugai Pharmaceutical for Sepsis: Likelihood of Approval
Tocilizumab is under clinical development by Chugai Pharmaceutical and currently in Phase II for Sepsis. According to GlobalData, Phase II...
LUNA-18 by Chugai Pharmaceutical for Solid Tumor: Likelihood of Approval
LUNA-18 is under clinical development by Chugai Pharmaceutical and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
Tocilizumab by Chugai Pharmaceutical for Follicular Lymphoma: Likelihood of Approval
Tocilizumab is under clinical development by Chugai Pharmaceutical and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase...
SAIL-66 by Chugai Pharmaceutical for Solid Tumor: Likelihood of Approval
SAIL-66 is under clinical development by Chugai Pharmaceutical and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
RAY-121 by Chugai Pharmaceutical for Immune Mediated Necrotizing Myopathy (IMNM): Likelihood of Approval
RAY-121 is under clinical development by Chugai Pharmaceutical and currently in Phase I for Immune Mediated Necrotizing Myopathy (IMNM). According...
RAY-121 by Chugai Pharmaceutical for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura): Likelihood of Approval
RAY-121 is under clinical development by Chugai Pharmaceutical and currently in Phase I for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)....
RAY-121 by Chugai Pharmaceutical for Dermatomyositis: Likelihood of Approval
RAY-121 is under clinical development by Chugai Pharmaceutical and currently in Phase I for Dermatomyositis. According to GlobalData, Phase I...
RAY-121 by Chugai Pharmaceutical for Antiphospholipid Syndrome: Likelihood of Approval
RAY-121 is under clinical development by Chugai Pharmaceutical and currently in Phase I for Antiphospholipid Syndrome. According to GlobalData, Phase...
RAY-121 by Chugai Pharmaceutical for Behcet Disease: Likelihood of Approval
RAY-121 is under clinical development by Chugai Pharmaceutical and currently in Phase I for Behcet Disease. According to GlobalData, Phase...
RAY-121 by Chugai Pharmaceutical for Bullous Pemphigoid: Likelihood of Approval
RAY-121 is under clinical development by Chugai Pharmaceutical and currently in Phase I for Bullous Pemphigoid. According to GlobalData, Phase...
Tocilizumab by Chugai Pharmaceutical for Follicular Lymphoma: Likelihood of Approval
Tocilizumab is under clinical development by Chugai Pharmaceutical and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase...
Emicizumab by Chugai Pharmaceutical for Acquired Hemophilia A: Likelihood of Approval
Emicizumab is under clinical development by Chugai Pharmaceutical and currently in Phase II for Acquired Hemophilia A. According to GlobalData,...
Emicizumab by Chugai Pharmaceutical for Von Willebrand Disease (vWD): Likelihood of Approval
Emicizumab is under clinical development by Chugai Pharmaceutical and currently in Phase I for Von Willebrand Disease (vWD). According to...
Emicizumab by Chugai Pharmaceutical for Acquired Hemophilia A: Likelihood of Approval
Emicizumab is under clinical development by Chugai Pharmaceutical and currently in Phase II for Acquired Hemophilia A. According to GlobalData,...